Alterations of rat liver lysosomes and smooth endoplasmic reticulum induced by the diazafluoranthen derivative AC-3579. II. Effects of the drug on phospholipid metabolism.
D000818:Animals; D001372:Aza Compounds / Q000494:pharmacology; D002247:Carbon Isotopes; D002855:Chromatography, Thin Layer; D004721:Endoplasmic Reticulum / Q000187:drug effects* / Q000378:metabolism; D004983:Ethanolamines / Q000378:metabolism; D005449:Fluorenes; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D007441:Intubation, Gastrointestinal; D008055:Lipids / Q000302:isolation & purification; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008247:Lysosomes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010710:Phosphates / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D010758:Phosphorus / Q000378:metabolism; D010759:Phosphorus Isotopes; D051381:Rats; D013997:Time Factors
D001372:Aza Compounds; D002247:Carbon Isotopes; D004983:Ethanolamines; D005449:Fluorenes; D006993:Hypnotics and Sedatives; D008055:Lipids; D010710:Phosphates; D010714:Phosphatidylethanolamines; D010743:Phospholipids; D010759:Phosphorus Isotopes; D010758:Phosphorus; C006177:2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide